The Asset Lead Medical Director leads development and delivery of U.S. Cardiovascular & Metabolic (CVM) Medical strategy for maridebart cafraglutide (MariTide), an investigational therapy being studied for obesity and obesity-related conditions. The role establishes the cross-indication scientific, evidence, stakeholder, and implementation foundation to support chronic weight management launch readiness and prepare the organization for growth in CVM. In partnership with the U.S. Medical Portfolio Lead, TA Head, Global Medical, and cross-functional colleagues, the role translates global strategy into an integrated U.S. Medical plan. The position leads U.S. CVM medical strategy, initially emphasizing chronic weight management launch support and early cardiovascular readiness. It develops an integrated evidence-based narrative connecting obesity with the broader care continuum; identifies U.S. evidence gaps and shapes evidence-generation priorities; and uses customer, field, market, and medical insights to inform strategy and execution. The role works with internal and external stakeholders on scientific communications, clinical development and evidence generation, stakeholder engagement, implementation science, launch readiness, governance, and medical training. It ensures medical activities comply with applicable laws, regulations, policies, and standard operating procedures, and uses planning and performance-management processes to assess progress and improve execution.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Senior